antibody

mAb anti- Amyloid Beta Peptide 42

MBS592412

0.5 mg

445 USD

monoclonal

mouse

nonconjugated

[CA9 3F8]

Antibody

mAb anti- Amyloid Beta Peptide 42

[Beta amyloid peptide 42]

[Ab42]

Monoclonal

IgG2b,k

[CA9 3F8]

Mouse

Human and other primates; mouse and rat.

This antibody recognizes the C-terminal sequence (MVGGVVIA) of Aß42 and full length Aß42.

Protein G Affinity Purified

Lyophilized from a solution in 0.01M PBS pH7.2

Store at -20°C

Immunohistochemistry (IHC)

Immunohistochemistry

Research Area: Aging and Neurodegenerative Diseases. Fusion Myeloma: Sp2/0-Ag14. Cross-reactivity: The antibody showed very weak to none-cross-reactivity with full length Aß43 and Aß40 in indirect ELISA. Reconstitution: Double distilled water is recommended to adujust the final concentration to 1.00 mg/mL

Immunogen: KLH conjugated to a short peptide (MVGGVVIA) with amino acid sequence corresponding to the C terminal of Aß42. Target Protein: C-terminal of amyloid beta peptide 42

Monoclonal Antibodies to Neurological Disorder Proteins

Description: Mouse monoclonal antibody to Cterminal of amyloid beta peptide 42 (Abeta42). Background: Amyloid beta peptide 42 (Abeta42) is best known for its role in the formation of senile plaques in the brain of patients with Alzheimer's disease. Abeta42 and Abeta40 are the two major amyloid peptides that are produced after cleavage of amyloid precursor protein by secretases. Abeta42 (42 amino acids) is very fibrillogenic. The beta pleated structure of Abeta42 constituents the initial and key component of the insoluble amyloid fibril in senile plaque. It is widely accepted that Abeta42 contributes to the pathogenesis of Alzheimer's disease. One proposition is that the deposition of amyloid fibril onto the brain tissue results in Alzheimer's disease. Another is that the neurotoxicity of Abeta42 oligomer is the cause of the disease.

0.5 mg

445 USD